{"id":45198,"date":"2025-10-29T17:48:59","date_gmt":"2025-10-29T09:48:59","guid":{"rendered":"https:\/\/flcube.com\/?p=45198"},"modified":"2025-10-29T17:49:01","modified_gmt":"2025-10-29T09:49:01","slug":"sihuan-pharmaceutical-secures-fast%e2%80%91track-designation-for-ng%e2%80%91350a-in-u-s-rectal-cancer-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45198","title":{"rendered":"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment"},"content":{"rendered":"\n<p><strong>Sihuan Pharmaceutical Holdings Group Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/0460:HKG\">HKG: 0460<\/a>) announced today that <strong>NG\u2011350A<\/strong>, a clinical\u2011stage oncolytic immunotherapy licensed from Akamis Bio via its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been granted <strong>Fast\u2011Track Designation<\/strong> by the U.S. Food and Drug Administration (FDA). The designation covers the treatment of <strong>locally advanced rectal cancer (LARC)<\/strong> with proficient mismatch repair (pMMR) function.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-ng-350a-brings-to-the-market\"><strong>What NG\u2011350A Brings to the Market<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 NG\u2011350A is an intravenously administered oncolytic virus engineered on Akamis\u2019 proprietary <strong>T\u2011SIGn<\/strong> platform. Inside the tumor, it drives expression of a CD40\u2011agonist monoclonal antibody, activating antigen\u2011presenting cells (APCs) in the tumor microenvironment and draining lymph nodes. This cascade recruits T\u2011cells and initiates a robust anti\u2011tumor immune response.<\/li>\n\n\n\n<li><strong>Clinical Evidence<\/strong> \u2013 In the <strong>FORTITUDE<\/strong> (monotherapy) and <strong>FORTIFY<\/strong> (pembrolizumab combination) studies, NG\u2011350A demonstrated a consistent safety and tolerability profile, coupled with evidence of tumor\u2011selective delivery, viral replication, and transgene expression.<\/li>\n\n\n\n<li><strong>Strategic Positioning<\/strong> \u2013 The Fast\u2011Track status accelerates the regulatory review process, potentially bringing this novel therapy to patients with LARC sooner than the typical pathway.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-partnerships-and-funding\"><strong>Key Partnerships and Funding<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Licensing Structure<\/strong> \u2013 The license for NG\u2011350A was obtained by Xuanzhu Biopharmaceutical, a subsidiary of Sihuan, from Akamis Bio.<\/li>\n\n\n\n<li><strong>Financial Backing<\/strong> \u2013 Akamis Bio, a clinical\u2011stage oncology company, secured USD\u202f60\u202fmillion in financing led by Sedgwick Yard in December\u202f2024 and entered a collaboration with Sunshine Lake Pharma for Greater China rights to NG\u2011350A.<\/li>\n\n\n\n<li><strong>Global Reach<\/strong> \u2013 The Fast\u2011Track designation in the U.S. complements Sihuan\u2019s existing global strategy to expand its oncology portfolio in both developed and emerging markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102800541_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025102800541_c.\"><\/object><a id=\"wp-block-file--media-b00548c7-2df7-4e20-bbba-f794c3fe8875\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102800541_c.pdf\">2025102800541_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025102800541_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b00548c7-2df7-4e20-bbba-f794c3fe8875\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG\u2011350A, a clinical\u2011stage oncolytic immunotherapy&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45201,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,930,146,670],"class_list":["post-45198","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-0460","tag-sihuan-pharmaceutical","tag-xuanzhu-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG\u2011350A, a clinical\u2011stage oncolytic immunotherapy licensed from Akamis Bio via its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been granted Fast\u2011Track Designation by the U.S. Food and Drug Administration (FDA). The designation covers the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) function.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45198\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment\" \/>\n<meta property=\"og:description\" content=\"Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG\u2011350A, a clinical\u2011stage oncolytic immunotherapy licensed from Akamis Bio via its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been granted Fast\u2011Track Designation by the U.S. Food and Drug Administration (FDA). The designation covers the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) function.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45198\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T09:48:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T09:49:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2912.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment\",\"datePublished\":\"2025-10-29T09:48:59+00:00\",\"dateModified\":\"2025-10-29T09:49:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2912.webp\",\"keywords\":[\"Cancer\",\"HKG: 0460\",\"Sihuan Pharmaceutical\",\"Xuanzhu Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45198#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45198\",\"name\":\"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2912.webp\",\"datePublished\":\"2025-10-29T09:48:59+00:00\",\"dateModified\":\"2025-10-29T09:49:01+00:00\",\"description\":\"Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG\u2011350A, a clinical\u2011stage oncolytic immunotherapy licensed from Akamis Bio via its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been granted Fast\u2011Track Designation by the U.S. Food and Drug Administration (FDA). The designation covers the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) function.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45198\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2912.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2912.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45198#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG\u2011350A, a clinical\u2011stage oncolytic immunotherapy licensed from Akamis Bio via its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been granted Fast\u2011Track Designation by the U.S. Food and Drug Administration (FDA). The designation covers the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) function.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45198","og_locale":"en_US","og_type":"article","og_title":"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment","og_description":"Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG\u2011350A, a clinical\u2011stage oncolytic immunotherapy licensed from Akamis Bio via its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been granted Fast\u2011Track Designation by the U.S. Food and Drug Administration (FDA). The designation covers the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) function.","og_url":"https:\/\/flcube.com\/?p=45198","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-29T09:48:59+00:00","article_modified_time":"2025-10-29T09:49:01+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2912.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45198#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45198"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment","datePublished":"2025-10-29T09:48:59+00:00","dateModified":"2025-10-29T09:49:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45198"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45198#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2912.webp","keywords":["Cancer","HKG: 0460","Sihuan Pharmaceutical","Xuanzhu Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45198#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45198","url":"https:\/\/flcube.com\/?p=45198","name":"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45198#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45198#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2912.webp","datePublished":"2025-10-29T09:48:59+00:00","dateModified":"2025-10-29T09:49:01+00:00","description":"Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG\u2011350A, a clinical\u2011stage oncolytic immunotherapy licensed from Akamis Bio via its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been granted Fast\u2011Track Designation by the U.S. Food and Drug Administration (FDA). The designation covers the treatment of locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) function.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45198#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45198"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45198#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2912.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2912.webp","width":1080,"height":608,"caption":"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45198#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sihuan Pharmaceutical Secures Fast\u2011Track Designation for NG\u2011350A in U.S. Rectal Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2912.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45198"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45198\/revisions"}],"predecessor-version":[{"id":45202,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45198\/revisions\/45202"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45201"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}